Loading clinical trials...
Loading clinical trials...
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Conditions
Interventions
Reparixin
Placebo
Locations
9
United States
University of California. Department of Surgery, Division of Transplantation
San Francisco, California, United States
The University of Chicago Medical Center
Chicago, Illinois, United States
Schulze Diabetes Institute University of Minnesota Medical School
Minneapolis, Minnesota, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
The University of Cincinnati Medical Center
Cincinnati, Ohio, United States
Thomas E. Starzl Transplantation Institute University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Start Date
February 1, 2014
Primary Completion Date
January 1, 2018
Completion Date
January 1, 2018
Last Updated
November 2, 2023
Lead Sponsor
Dompé Farmaceutici S.p.A
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions